Latest Form 4 insider transactions

Jacob D. Cohen and 1 other reported changes in beneficial ownership of Mangoceuticals, Inc. common stock on September 30, 2025.

Eugene M Johnston, CFO of Mangoceuticals, Inc., received 100,000 shares of common stock on July 28, 2026.

Alex P. Hamilton, a Director of Mangoceuticals, Inc., received 100,000 shares of common stock on July 28, 2026.

Tor Olav Troim, a Director of Borr Drilling Ltd, purchased 1,500,000 shares of common stock on October 5, 2026 for $4.13 per share.

Indivior Pharmaceuticals, Inc. has issued supplemental disclosures regarding its merger with Supernus Pharmaceuticals, Inc., addressing recent litigation and providing updated financial advisor analysis.

Supernus Pharmaceuticals files supplemental disclosures to its proxy statement regarding the merger with Indivior, addressing stockholder litigation and providing updated financial advisor analysis.

Gilead Raday, Chief Operating Officer of RedHill Biopharma Ltd., sold 14,310,000 shares of common stock on October 1, 2026 for $0.00 per share.

Rajesh Pankaj, Chief Technology Officer of InterDigital, Inc., sold 1,500 shares of common stock on October 5, 2026 for $334.32 per share.

L1 Capital Pty Ltd reported changes in beneficial ownership of Anteris Technologies Global Corp. common stock on October 2, 2026.

Mark P Frissora, a Director of Bioadaptives, Inc., reported a transaction in 15,625 shares of common stock on 2026-10-01-05:00.

Brian Hongdi Gu, Vice Chairman & Co-President of Xpeng Inc., reported multiple transactions in common stock on October 2, 2026.

Chandan Basho, COO and CFO of Astrana Health, Inc., reported a transaction in 2,092 shares of common stock on October 2, 2026.

Hudson Blake Leogrande, a Director of Prenetics Global Ltd, reported multiple transactions in common stock on October 4, 2026.

Theodore Zhu, a Director of Predictive Oncology Inc., received 733 shares of common stock on October 1, 2026.

Charles Lee Nuzum Sr, a Director of Predictive Oncology Inc., received 733 shares of common stock on October 1, 2026.

Matthew Hawryluk, a Director of Predictive Oncology Inc., received 733 shares of common stock on October 1, 2026.

Daniel E Handley, a Director of Predictive Oncology Inc., received 528 shares of common stock on October 1, 2026.

Thorsten Dirks, a Director of Predictive Oncology Inc., reported multiple transactions in common stock on April 20, 2026.

Clair Gregory St. Sr, a Director of Predictive Oncology Inc., received 733 shares of common stock on October 1, 2026.

Anthony Michael Denier, President and a Director of Webull Corp, sold 53,846 shares of common stock on October 5, 2026 for $7.33 per share.

Benjamin Pham, Chief Financial Officer and a Director of Asset Entities Inc., sold 4,209 shares of common stock on October 5, 2026 for $31.33 per share.

Matthew Ryan Cole, Chief Executive Officer and a Director of Asset Entities Inc., sold 58,789 shares of common stock on October 5, 2026 for $31.33 per share.

Jonathan R Macey, a Director of Asset Entities Inc., sold 6,700 shares of common stock on October 5, 2026 for $30.32 per share.

C.H. Robinson announced its acquisition of RXO, aiming to create a more comprehensive logistics platform and unlock significant shareholder value.

C.H. Robinson announced its acquisition of RXO, aiming to create a more comprehensive logistics platform and unlock significant shareholder value.

James Lavish, a Director of Asset Entities Inc., sold 6,000 shares of common stock on October 5, 2026 for $30.75 per share.

Brian Logan Beirne, Chief Legal Officer and a Director of Asset Entities Inc., sold 20,077 shares of common stock on October 5, 2026 for $31.33 per share.

Arshia Sarkhani, Chief Marketing Officer and a Director of Asset Entities Inc., sold 5,634 shares of common stock on October 5, 2026 for $31.33 per share.

Wolfe Repass, Chief Financial Officer of FTAC Emerald Acquisition Corp., sold 1,231 shares of common stock on October 1, 2026 for $0.53 per share.

William Brian Poppic Reeves, Chief Executive Officer and 10% owner of FTAC Emerald Acquisition Corp., sold 5,304 shares of common stock on October 1, 2026 for $0.53 per share.